Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination

References

• Centers for Disease Control and Prevention. Shingles overview. 2018 [accessed 2018 Jan 18 2019]. https://www.cdc.gov/shingles/about/overview.html
   Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). Mmwr. 2008;57:1–11.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Complications of Shingles. 2019 [accessed 2020 June 6]. https://www.cdc.gov/shingles/about/complications.html
   Google Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the Advisory Committee on Immunization Practices for use of Herpes Zoster vaccines. MMWR. 2018;67(3):103–08. doi:10.15585/mmwr.mm6703a5.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage. 2004;28:396–411.
   PubMed Web of Science ®Google Scholar
• Gan EY, Tian EA, Tey HL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol. 2013;14(2):77–85. doi:10.1007/s40257-013-0011-2.
   PubMed Web of Science ®Google Scholar
• Nalamachu S, Morley-Forster P. Diagnosing and managing postherpetic neuralgia. Drugs Aging. 2012;29(11):863–69. doi:10.1007/s40266-012-0014-3.
   PubMed Web of Science ®Google Scholar
• Thakur R, Philip AG. Chronic pain perspectives: Treating herpes zoster and postherpetic neuralgia: an evidence-based approach. J Fam Pract. 2012;61:S9–15.
   PubMed Web of Science ®Google Scholar
• John AR, Canaday DH. Herpes Zoster in the older adult. Infect Dis Clin North Am. 2017;31(4):811–26. doi:10.1016/j.idc.2017.07.016.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services (HHS). 5-Point strategy to combat the opioid crisis. 2020 [accessed 2020 Sep 15]. https://www.hhs.gov/opioids/about-the-epidemic/hhs-response/index.html
   Google Scholar
• Johnson P, Becker L, Halpern R, Sweeney M. Real-World treatment of post-herpetic neuralgia with Gabapentin or Pregabalin. Clin Drug Investig. 2013;33:35–44. doi:10.1007/s40261-012-0030-4.
   PubMed Web of Science ®Google Scholar
• Shukla S, Wiggall A, Jan S Assessing opioid trends and management of members with general pain conditions. Academy of Managed Care Pharmacyʻs Nexus Meeting; Dallas, TX, USA. 2017.
   Google Scholar
• Gudin J, Khangulov VS, Skaar JR, Peyerl FW, Patel K. The treatment of postherpetic neuralgia reveals widespread use of opioids, cns depressants, and polypharmacy. Value Health. 2016;19:A1–A318. doi:10.1016/j.jval.2016.03.1018.
   PubMedGoogle Scholar
• Suaya JA Zoster costs in US adults with diabetes. AAFP Family Medicine Experience (FMX). San Antonio, TX, USA, 2017.
   Google Scholar
• Li Q, Chen SY, Burstin SJ, Levin MJ, Suaya JA. Cost of Herpes Zoster in patients with selected immune-compromised conditions in the United States. Open Forum Infect Dis. 2016;3:ofw067.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Inc. SHINGRIX (Zoster vaccine recombinant, adjuvanted). Prescribing Inf. 2019.
   Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J et al. Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96.
   PubMed Web of Science ®Google Scholar
• IBM Watson Health. IBM market scan research databases for life sciences researchers. 2018 [accessed 2020 Sep 15]. https://www.ibm.com/downloads/cas/0NKLE57Y
   Google Scholar
• Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2011;83:1432–37.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–40. doi:10.1016/j.jclinepi.2008.01.006.
   PubMed Web of Science ®Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–19.
   PubMed Web of Science ®Google Scholar
• Meyers JL, Madhwani S, Rausch D, Candrilli SD, Krishnarajah G, Yan S. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States. Hum Vaccin Immunother. 2017;13(8):1861–72. doi:10.1080/21645515.2017.1324373.
   PubMed Web of Science ®Google Scholar
• Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Costs of herpes zoster complications in older adults: A cohort study of US claims database. Vaccine. 2019;37:1235–44. doi:10.1016/j.vaccine.2018.11.079.
   PubMed Web of Science ®Google Scholar
• Wedderburn RWM. Quasi-Likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika. 1974;61:439–47.
   Web of Science ®Google Scholar
• Mihaylova B, Briggs A, O'Hagan A, and Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897–916. doi:10.1002/hec.1653.
   PubMed Web of Science ®Google Scholar
• Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213–21. doi:10.1080/21645515.2017.1345399.
   PubMed Web of Science ®Google Scholar
• Patterson B, Herring WL, van Oorschot D, Curran D, Carrico J, Zhang Y et al. Public health and economic impact of adjuvanted recombinant Zoster vaccine adoption for a large, integrated delivery network: utilizing real‐World epidemiological data in a budget impact model. National Harbor, MD: Academy of Managed Care Pharmacy (AMCP) Nexus; 2019.
   Google Scholar
• Poirrier JE, Carrico J, DeMartino JK, Hicks KA, Stoddard JJ, Nagar SP, and Meyers J. . In: Open Forum Infect Dis: 7(Suppl 1). S527; 2020. doi:10.1093/ofid/ofaa439.1182.
   Google Scholar
• Centers for Disease Control and Prevention. 2018 annual surveillance report of drug-related risks and outcomes—United States. Surveillance special report. 2018 [cited 2019 1 May 2019]; https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf
   Google Scholar
• Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015. MMWR. 2017;66(10):265–69. doi:10.15585/mmwr.mm6610a1.
   PubMedGoogle Scholar
• Hooten WM, St Sauver JL, McGree ME, Jacobson DJ, Warner DO. Incidence and risk factors for progression from short-term to episodic or long-term opioid prescribing: a population-based study. Mayo Clin Proc. 2015;90(7):850–56. doi:10.1016/j.mayocp.2015.04.012.
   PubMed Web of Science ®Google Scholar
• Schieber LZ, Guy GP Jr., Seth P, Young R, Mattson CL, Mkosz CA, Schieber RA. Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006-2017. JAMA Netw Open. 2019;2(3):e190665. doi:10.1001/jamanetworkopen.2019.0665.
   PubMed Web of Science ®Google Scholar
• Rutkow L, Vernick JS, Alexander GC. More states should regulate pain management clinics to promote public health. Am J Public Health. 2017;107:240–43.
   PubMed Web of Science ®Google Scholar
• National Conference of State Legislatures. Prescribing policies: states confront opioid overdose epidemic. 2019 [cited 2021 Jul 15].
   Google Scholar
• Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:241–48. doi:10.1056/NEJMsa1406143.
   PubMed Web of Science ®Google Scholar
• Bohnert ASB, Guy GP Jr., Losby JL. Opioid prescribing in the United States before and after the centers for disease control and preventionʻs 2016 opioid guideline. Ann Intern Med. 2018;169(6):367–75. doi:10.7326/M18-1243.
   PubMed Web of Science ®Google Scholar
• Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of Pregabalin and Gabapentin. Drugs. 2017;77:403–26. doi:10.1007/s40265-017-0700-x.
   PubMed Web of Science ®Google Scholar
• Klimas J, Gorfinkel L, Fairbairn N, Amato L, Ahamad K, Nolan S, Simel DL, Wood E. Strategies to identify patient risks of prescription opioid addiction when initiating opioids for pain: a systematic review. JAMA Netw Open. 2019;2(5):e193365. doi:10.1001/jamanetworkopen.2019.3365.
   PubMed Web of Science ®Google Scholar
• Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol. 2008;16(5):405–16. doi:10.1037/a0013628.
   PubMed Web of Science ®Google Scholar
• Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-Effectiveness of an adjuvanted recombinant Zoster vaccine in older adults in the United States. Vaccine. 2018;36:5037–45. doi:10.1016/j.vaccine.2018.07.005.
   PubMed Web of Science ®Google Scholar